Signaling Through the Erythropoietin Receptor Affects Angiogenesis in Retinovascular Disease
暂无分享,去创建一个
[1] M. Hartnett,et al. Erythropoietin Receptor Signaling Supports Retinal Function after Vascular Injury. , 2020, The American journal of pathology.
[2] Phuong T. Vu,et al. A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants. , 2020, The New England journal of medicine.
[3] M. Yaseri,et al. Combination of intravitreal bevacizumab and erythropoietin versus intravitreal bevacizumab alone for refractory diabetic macular edema: a randomized double-blind clinical trial , 2019, Graefe's Archive for Clinical and Experimental Ophthalmology.
[4] Lois E. H. Smith,et al. Erythropoietin serum levels, versus anaemia as risk factors for severe retinopathy of prematurity , 2018, Pediatric Research.
[5] T. Kafri,et al. Gene therapy knockdown of VEGFR2 in retinal endothelial cells to treat retinopathy , 2018, Angiogenesis.
[6] P. Hüppi,et al. Long-term neuroprotective effect of erythropoietin on executive functions in very preterm children (EpoKids): protocol of a prospective follow-up study , 2018, BMJ Open.
[7] D. Ribatti,et al. Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma , 2018, Annals of Hematology.
[8] R. Heinrich,et al. Alternative Erythropoietin Receptors in the Nervous System , 2018, Journal of clinical medicine.
[9] J. Prchal,et al. Erythropoietin Signaling Increases Choroidal Macrophages and Cytokine Expression, and Exacerbates Choroidal Neovascularization , 2018, Scientific Reports.
[10] N. Lois,et al. Erythropoietin in diabetic retinopathy , 2017, Vision Research.
[11] P. Solár,et al. Erythropoietin and Its Angiogenic Activity , 2017, International journal of molecular sciences.
[12] M. Martinez-Castellanos,et al. Vascular changes on fluorescein angiography of premature infants with low risk of retinopathy of prematurity after high oxygen exposure , 2017, International Journal of Retina and Vitreous.
[13] U. Schiefer,et al. Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial—study protocol , 2016, BMJ Open.
[14] H. Votavova,et al. Delayed hemoglobin switching and perinatal neocytolysis in mice with gain-of-function erythropoietin receptor , 2015, Journal of molecular medicine.
[15] P. Heagerty,et al. Neuroprotective potential of erythropoietin in neonates; design of a randomized trial , 2015, Maternal Health, Neonatology and Perinatology.
[16] Zhihong Yang,et al. VEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesis. , 2014, The American journal of pathology.
[17] Sara R. Savage,et al. Hypoxia-induced expression of VEGF splice variants and protein in four retinal cell types. , 2013, Experimental eye research.
[18] J. Flannery,et al. Short hairpin RNA-mediated knockdown of VEGFA in Müller cells reduces intravitreal neovascularization in a rat model of retinopathy of prematurity. , 2013, The American journal of pathology.
[19] B. Chang,et al. Survey of common eye diseases in laboratory mouse strains. , 2013, Investigative ophthalmology & visual science.
[20] V. Narendran,et al. Aggressive posterior retinopathy of prematurity in large preterm babies in South India , 2012, Archives of Disease in Childhood: Fetal and Neonatal Edition.
[21] A. Cerami,et al. The Receptor That Tames the Innate Immune Response , 2012, Molecular medicine.
[22] Michael H. Elliott,et al. Müller Cell-Derived VEGF Is Essential for Diabetes-Induced Retinal Inflammation and Vascular Leakage , 2010, Diabetes.
[23] N. Petrovsky,et al. Association between erythropoietin gene polymorphisms and diabetic retinopathy. , 2010, Archives of ophthalmology.
[24] S. Tsang,et al. Erythropoetin receptor expression in the human diabetic retina , 2009, BMC Research Notes.
[25] Lois E. H. Smith,et al. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. , 2009, Investigative ophthalmology & visual science.
[26] Lois E. H. Smith,et al. Erythropoietin deficiency decreases vascular stability in mice. , 2008, The Journal of clinical investigation.
[27] J. Nielsen,et al. Functional and immunochemical characterisation of different antibodies against the erythropoietin receptor , 2007, Journal of Neuroscience Methods.
[28] K. Fleming,et al. Dimerization of the erythropoietin receptor transmembrane domain in micelles. , 2007, Journal of molecular biology.
[29] J. C. Kim,et al. Involvement of circulating endothelial progenitor cells and vasculogenic factors in the pathogenesis of diabetic retinopathy , 2007, Eye.
[30] A. Cerami,et al. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. , 2006, Kidney international.
[31] C. Begley,et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. , 2006, Blood.
[32] S. Masuda,et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. , 2005, The New England journal of medicine.
[33] D. Barber,et al. Turning cells red: signal transduction mediated by erythropoietin. , 2005, Trends in cell biology.
[34] T. Townes,et al. Mouse model of congenital polycythemia: Homologous replacement of murine gene by mutant human erythropoietin receptor gene. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[35] Rudolf Jaenisch,et al. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor , 1995, Cell.
[36] Lois E. H. Smith,et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[37] Lois E. H. Smith,et al. Oxygen-induced retinopathy in the mouse. , 1994, Investigative ophthalmology & visual science.